485 related articles for article (PubMed ID: 30638853)
1. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
[TBL] [Abstract][Full Text] [Related]
2. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
[TBL] [Abstract][Full Text] [Related]
3. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
[TBL] [Abstract][Full Text] [Related]
4. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06.
Morinaga S; Takita M; Yoshizawa A; Kamei K; Nakamori S; Ishihara S; Kuramochi H; Yokoyama Y; Uchiyama T; Murohisa G; Ishigaki M; Todaka A; Fukutomi A
Pancreas; 2020; 49(10):1372-1377. PubMed ID: 33122527
[TBL] [Abstract][Full Text] [Related]
6. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
[TBL] [Abstract][Full Text] [Related]
8. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
[TBL] [Abstract][Full Text] [Related]
9. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Tong H; Fan Z; Liu B; Lu T
Sci Rep; 2018 Jun; 8(1):8666. PubMed ID: 29875415
[TBL] [Abstract][Full Text] [Related]
10. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
12. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644
[TBL] [Abstract][Full Text] [Related]
13. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836
[TBL] [Abstract][Full Text] [Related]
14. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
[TBL] [Abstract][Full Text] [Related]
16. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
McIntyre CA; Cohen NA; Goldman DA; Gonen M; Sadot E; O'Reilly EM; Varghese AM; Yu KH; Balachandran VP; Soares KC; D'Angelica MI; Drebin JA; Kingham TP; Allen PJ; Wei AC; Jarnagin WR
J Surg Oncol; 2022 Mar; 125(3):425-436. PubMed ID: 34719035
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
[TBL] [Abstract][Full Text] [Related]
19. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Ozaka M; Ishii H; Sato T; Ueno M; Ikeda M; Uesugi K; Sata N; Miyashita K; Mizuno N; Tsuji K; Okusaka T; Furuse J
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1017-1023. PubMed ID: 29633005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
